Research Reports

image34

Ludlow Investor Mailing List

Join for research updates and investment alerts

CBD / Cannabis Stocks

Ludlow Research issues a special situation opinion on the CBD and cannabis sector, and calls a bottom in stocks associated within this sector, based on changes in regulatory and fundamentals within the industry
Related:  MJ CVSI NBEV CIIX TAUG EDXC SWRM BKIT SING PURA

Updated: Nov. 11, 2019 (pdf)

Download

ChineseInvestors.com (OTCQB:CIIX)

 Founded in 1999, ChineseInvestors.com (OTCQB:CIIX)  endeavors to be an innovative company providing: (a) real-time market  commentary, analysis, and educational-related services in Chinese  language character sets (traditional and simplified); (b) advertising  and public relation-related support services; and (c) retail, online and  direct sales of hemp-based products and other health-related products.  For more information visit www.chineseInvestors.com
 

Updated: Nov. 12, 2019 (pdf)

Download

Tauriga Sciences, Inc. (OTC:TAUG)

Tauriga Sciences, Inc. (TAUG) is a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities. One such opportunity on which the Company has acted, involves the Company having entered into the cannabidiol (or “CBD”) infused chewing gum product business, as more fully described above and in prior press releases. This CBD infused chewing gum product has been branded under the following name: Tauri-Gum™. The Company is currently in production of three distinct flavors of Tauri-Gum™: MINT, BLOOD ORANGE, and POMEGRANATE. Further, the Company continues to identify and evaluate additional potential opportunities to generate revenue, as well as shareholder value, and leverage its resources and expertise to build a diversified and sustainable business model. Please visit our corporate website at www.tauriga.com

 

Updated: Nov. 12, 2019 (pdf)

Download

American Premium Water (OTC:HIPH)

 American Premium Water (OTC: HIPH) is a diversified luxury consumer products company focused on businesses in the health and beauty and biotech sectors. The company is focused on harnessing the powers of hydrogen and Nano technologies paired with cannabidiol (CBD) to treat health disorders and enhance quality of life. This business model aims to market emerging fashion brands by leveraging classic retail partners and incorporating disruptive blockchain technologies to expand the retail footprint. The company’s portfolio includes the LALPINA Hydro and LALPINA Hydro CBD brands (www.LalpinaInc.com

Updated: Nov. 12, 2019 (pdf)

Download

Link Reservations (OTC:LRSV)

LinkResPet, a subsidiary of Link Reservations Inc (OTC: LRSV), is CBD Petcare provider dedicated to improving the health and life conditions of pets worldwide. Developing and marketing hemp-based CBD products for cats, dogs and horses, Link Reservations Inc is currently present in Europe and in the US. A pioneer in the area, LinkResPet products can be found online on: www.linkrespet.com 

Updated: Sept 13, 2019 (pdf)

Download

Hammer Fiber (OTCQB:HMMR)

  •  Hammer Fiber Optics (OTCQB:HMMR)  is a registered Competitive Local Exchange Carrier in New Jersey that  offers services throughout the New Jersey region, as well as  Philadelphia and New York. Along with fiber transit solutions, VoIP  platforms, Ethernet connectivity and managed services to businesses  ranging from small to enterprise; Hammer Fiber also serves residential  and small business markets with broadband, voice and video. For more  information visit www.hammerfiber.com
     

Updated: Jan. 25, 2019 (pdf)

Download

Auris Medical Holding (EARS)

  •  Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental disorders supportive care. The company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). This program is currently in Phase 1. In addition Auris Medical has two Phase 3 programs under development: AM-111 for sudden sensorineural hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. 

Updated: Oct. 18, 2018 (pdf)

Download